AbbVie partners on an Opdivo combo study with Bristol-Myers; Intercept tumbles on FDA warning

⇨ AbbVie wants to explore how a combination of its anti-c-Met antibody drug ABBV-399 will work in combination with Bristol-Myers’ Opdivo in treating non-small cell lung cancer. This is the latest in hundreds of combo studies with checkpoint drugs, and AbbVie is taking the lead on executing the Phase Ib study.

⇨ Shares of Intercept Pharmaceuticals $ICPT tumbled badly after the FDA issued a warning about the risk of death and injury patients face taking their drug Ocaliva. Some analysts speculate that the FDA may be about to slap a black box warning on the drug — sold for primary biliary cholangitis — that could crimp sales.

⇨ Interested in the industry’s pipeline of new Alzheimer’s drugs? If so, you should check out PhRMA’s new list covering dozens of experimental meds in the clinic.